An observational study in Neuroblastoma, sponsored by RECORDATI GROUP. Active, not recruiting at 13 sites in 7 countries. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by RECORDATI GROUP · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Neuroblastoma with a site in France — 10 open to participants now, 15 under way, 2 of them phase 3. Neuroblastoma · France.
Among the 54 studies in Neuroblastoma with a site in France, this one is one of 3 that started in 2019, is one of 4 observational ones, reaches primary completion later than 13 of the 14 other live ones, and was the 43rd registered.
676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.
Browse Neuroblastoma studies →10 of the 54 studies in Neuroblastoma with a site in France are open now. Recruiting first, the newest first:
Renaissance Pharma Ltd. · Sites in France, United States, Canada and 4 more countries
Ages 18 mo–18 yrs
University Hospital, Clermont-Ferrand · Sites in France
Ages 2–45
Merck Sharp & Dohme LLC · Sites in France, United States, Australia and 20 more countries
Ages 6 mo–25 yrs
University Hospital, Strasbourg, France · Sites in France
Ages 2–25
Institut Curie · Sites in France, Czechia, Norway and 1 more country
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.
This study: 1 Year to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 28 · Phase 3 7 · Phase 4 1
First in 1994; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 125 is close to the median of 123 across 84 observational studies indexed under Neuroblastoma.
Median enrollment 102 across the 44 interventional studies, 107 across the 4 observational. Of the 32 that completed or were terminated, 10 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 54 have an industry lead sponsor. The 10 most frequent:
RECORDATI GROUP is the lead sponsor of 21 studies on the registry; 3 are open to participants now.
RECORDATI GROUP has 1 study filed under Neuroblastoma — fewer than ten, so there is no comparison to draw.
5 of the studies in Neuroblastoma with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04221035Phase 3Gustave Roussy, Cancer Campus, Grand ParisHigh-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) | 2026-11 |
| NCT03975829Novartis PharmaceuticalsPediatric Long-Term Follow-up and Rollover Study | 2026-11-24 |
| NCT03496402Institut CurieBiological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) | 2027-04-19 |
| NCT02650401Hoffmann-La RocheStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | 2027-06-30 |
| NCT07141862University Hospital, Clermont-FerrandFertility Preservation in Children With Solid Tumors: Detection of Residual Disease by a Sensitive Method | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 54 studies in Neuroblastoma with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a non-interventional, multi-national, observational, prospective patient registry to further evaluate the effectiveness and safety of dinutuximab beta - a monoclonal immunoglobulin G 1 (IgG1) antibody, to obtain information on survival, pain severity and incidence of neuro-toxicity, visual impairment, capillary leak syndrome, cardiovascular events, hypersensitivity reactions and long-term safety.
Rationale and Background:
Neuroblastoma, is the most common extra-cranial solid tumour in children. Most patients with neuroblastoma are diagnosed under the age of 5 years and most present with metastatic disease and/or high-risk features. Despite the introduction of novel treatment strategies, including high-dose chemotherapy followed by autologous stem cell transplantation (ASCT), the outcome of these patients remains poor.
Dinutuximab beta is a chimeric monoclonal immunoglobulin G 1 (IgG1) antibody that is specifically directed against the carbohydrate moiety of disialoganglioside antigen (GD2), which is overexpressed on neuroblastoma cells. By binding to neuroblastoma cells, dinutuximab beta can induce both complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC).
The efficacy of dinutuximab beta has been evaluated in a randomised controlled trial comparing the administration of dinutuximab beta with or without interleukin 2 (IL-2) in the first-line treatment of patients with high-risk neuroblastoma and in two singlearm studies in the relapsed/refractory setting. The efficacy and safety of dinutuximab beta will further be evaluated in this registry that will provide information on survival, pain severity and incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events, hypersensitivity reactions and long-term safety.
Study Design:
This is a non-interventional, multi-national, observational, prospective patient registry of patients with high-risk neuroblastoma being treated with the monoclonal antibody dinutuximab beta. The efficacy and safety of dinutuximab beta will further be evaluated in this registry that will provide information on survival, pain severity and incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events, hypersensitivity reactions and long-term safety.
Research Questions and Objectives:
Primary objectives:
Secondary objectives:
Population:
Patients diagnosed with high-risk neuroblastoma who are starting treatment with dinutuximab beta in the standard clinical practice setting or participating in a clinical trial where dinutuximab beta is provided according to the indication as per the country/regional marketing authorisation, provide consent/assent and are willing to be followed up for up to 10 years.
Study Size:
It is planned to enroll a sufficient number of patients (estimated at 125) such that 100 patients will have completed all five treatment courses of dinutuximab beta. It is anticipated that this will result in 40-50 patients who are progression free at 10 years.
Data Sources:
Data will be collected from physicians using an electronic data capture (EDC) system. The electronic case report forms (eCRFs) will be designed to gather data from the medical records at baseline, during treatment and at normal clinical practice follow up visits.
Data Analysis:
The safety analysis set, containing all patients treated with at least one dose of dinutuximab beta will be considered for safety and efficacy analyses. All baseline, treatment period and follow up characteristics will be summarized using descriptive statistics. Endpoints addressing primary and secondary analysis will include 95% confidence intervals (CIs) including the Clopper Pearson method for binomial, log-log transform for survival. OS, PFS and EFS will be analysed using Kaplan-Meier methods.
Variables:
Baseline (prior to start of treatment): Demographics, clinical trial participation, neuroblastoma disease history, and presence or absence of neurotoxicity, visual impairment, and cardiovascular abnormality.
Treatment period (up to end of last 35 day course of 5th cycle of treatment):
Dosing regimen, total cumulative amount of dinutuximab beta per course, concomitant medications during course (IL-2, retinoic acid and/or antihistamines), daily analgesics (opioids, gabapentin/ pregabalin and/or non-opioid analgesics and other neuropathic pain treatments), daily pain assessment during infusion of dinutuximab beta, occurrence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events, and hypersensitivity reactions, adverse events (AEs)/serious adverse events (SAEs) treatment interruptions and discontinuations, progression of disease, date and cause of death, reason for study withdrawal (if applicable) Follow up (from end of last 35 day course of 5th cycle of treatment): Status of neurotoxicity, visual impairment, cardiovascular events, (resolved, not resolved), SAEs and adverse drug reaction (ADRs), progression of disease, date and cause of death, reason for study withdrawal (if applicable).
Patients diagnosed with high-risk neuroblastoma who are starting treatment with dinutuximab beta in the standard clinical practice setting or participating in a clinical trial where dinutuximab beta is provided according to the indication as per the country/regional marketing authorisation, provide consent/assent and are willing to be followed up for up to 10 years. Centers who treat neuroblastoma patients with dinutuximab beta will be invited to participate in the registry. This includes networks such as the Society of Paediatric Oncology for the Treatment of Neuroblastoma (SIOPEN) in Europe.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients meeting the following criteria will be considered for inclusion into the registry:
Exclusion Criteria:
Patient will not be eligible for inclusion if the following criterion applies:
Data will be collected on dose, total cumulative amount of dinutuximab beta per course, dose interruptions, dose discontinuations, prophylactic treatment, use of all concomitant analgesia, assessments of pain, and occurrence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions and other AEs.
Assessment of the severity of pain experienced by participants during treatment with dinutuximab beta
Assessment of pain severity experienced by participants during the period of first dose of dinutuximab beta to the end of last 35 day course of 5th cycle of treatment
Time frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)
Number of participants using analgesics during treatment with dinutuximab beta
Use of analgesics during the period of first dose of dinutuximab beta to end of last 35 day course of 5th cycle of treatment
Time frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)
Incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions
Incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions up to the end of the last 35 day course of 5th cycle of treatment
Time frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)
Number of participants experiencing serious adverse events (SAEs) and adverse drug reactions (ADRs) during treatment with dinutuximab beta
Number of participants experiencing serious adverse events (SAEs) and adverse drug reactions (ADRs) following the end of the last 35 day course of 5th cycle of treatment
Time frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)
Overall Survival (OS)
Overall Survival (OS) following the end of the last 35 day course of 5th cycle of treatment
Time frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)
Progression free survival (PFS)
Progression free survival (PFS) following the end of the last 35 day course of 5th cycle of treatment
Time frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)
Event Free Survival (EFS)
Event Free Survival (EFS) following the end of the last 35 day course of 5th cycle of treatment
Time frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2019 (actual). Primary completion is estimated for Jun 2036, 201 months after the start.
Of 34 observational studies under Neuroblastoma, half reached primary completion within 213 months of starting (the median), counting those still running; a quarter within 74 and three quarters within 304. This study's planned 201 months is close to that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Mar 2032 → Jun 2036 and completion Jun 2032 → Jun 2036.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.